New tetanus antibody drug shows promise in early trial

NCT ID NCT05625477

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested an experimental drug called TNM002 in 240 healthy Chinese adults to see if it can protect against tetanus as well as the standard treatment. Participants received a single injection of TNM002 at different doses, the standard tetanus antibody, or a placebo. The main goal was to measure whether TNM002 raised tetanus-fighting antibodies to protective levels. The trial is now complete, and results will show if this new drug is a safe and effective alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TNM002 injection (an experimental antibody)
What this could lead to
If successful, TNM002 could offer a new option to prevent tetanus after injury, potentially with fewer side effects or easier production than current treatments.
What could go wrong
This is an early-phase trial with only 240 participants, so results may not apply to everyone. The experimental drug may not work as well as existing tetanus shots, and allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TETANUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • PKUCare Luzhong Hospital

    Zibo, Shandong, China

  • The First Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Wuxi People's Hospital

    Wuxi, Jiangsu, China

  • Yunnan Provincial Hospital of Traditional Chinese Medicine

    Kunming, Yunnan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.